{"filings":[{"id":99754,"accession_number":"0000917520-26-000044","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Integra LifeSciences shareholders approve 3.55M share increase to equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 3 to increase shares available under the plan by 3,550,000 to 24,250,000 total shares.","All 7 director nominees were elected; Barbara B. Hill received the most votes against (7,042,475).","Ratification of PricewaterhouseCoopers as 2026 auditor passed with 72,313,820 votes for.","Advisory say-on-pay approved with 68,472,769 votes for.","Equity plan amendment received 68,005,433 votes for and 1,269,231 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99753,"accession_number":"0000917520-26-000034","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.","Mojdeh Poul departed as President and CEO and from the Board effective April 30, 2026; she receives $566,526 lump sum.","Essig receives $1,075,000 base salary, 125% target bonus, and initial equity awards totaling $8 million in RSUs and options.","Michael McBreen appointed Chief Commercial Officer with base salary $660,000 and $1,000,000 one-time equity award.","Essig previously served as Integra's CEO from 1997 to 2012 and as Executive Chairman from February 2024 to June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99752,"accession_number":"0000917520-26-000033","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.","Adjusted EPS $0.54 vs $0.41; adjusted gross margin 64.1% vs 62.2%. Adjusted EBITDA $76.2M (19.4% rev).","Specialty Surgery rev $283.1M (+0.9% rep, -0.6% organic); Tissue Reconstruction $108.8M (+6.7% rep, +6.4% organic).","Reaffirms FY rev guidance $1.662B-$1.702B; raises adj. EPS guidance to $2.40-$2.50 from $2.30-$2.40.","Braintree facility on track to begin SurgiMend production by end of June for Q4 launch; PriMatrix/Durepair returning."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":391918000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99751,"accession_number":"0000917520-26-000019","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Integra LifeSciences amends $150M A/R facility, extends termination to April 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Scheduled termination date of $150M accounts receivable securitization facility extended to April 10, 2029.","Amends representations, covenants, and concentration limits under the Receivables Financing Agreement.","Also amends Purchase and Sale Agreement with similar covenant changes; PNC Bank remains administrative agent.","The Bank of Nova Scotia remains a committed lender and group agent under the facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115934,"accession_number":"0000917520-26-000008","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q4 rev -1.7% organic; FY GAAP loss $6.74/sh on $511M goodwill impairment; 2026 adj EPS guidance $2.30-$2.40","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.","FY 2025 revenues $1,635.2M (+1.5% reported, -0.7% organic); GAAP net loss $516.5M ($6.74/sh) includes $511M goodwill impairment.","Codman Specialty Surgical segment rev $323.3M (+2.7% reported); Tissue Technologies rev $111.6M (-12.8% reported) driven by MediHoney remediation and Integra Skin comp.","2026 guidance: revenues $1,662-$1,702M (0.8%-3.3% organic growth); adj EPS $2.30-$2.40; Q1 2026 rev $375-$390M.","Transformation plan simplifies operating model targeting $25-$30M savings in 2026; net debt $1.6B, leverage 4.5x, liquidity $516M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":1635245000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132349,"accession_number":"0000917520-25-000100","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra adopts CIC severance program; CFO gets 2x multiple","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Program effective Jan 1, 2026; covers Lea Knight (CFO), Robert Davis, Michael McBreen, Harvinder Singh.","Qualifying termination within 2 years after a change in control triggers severance: 1.5x (2x for CFO) of base salary plus target bonus.","Benefits include lump-sum cash, pro-rated bonus, 18 months of COBRA subsidies, and 12 months of outplacement.","Program automatically extends to 2 years post-change in control; subject to release and 'best pay cap' excision tax limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132348,"accession_number":"0000917520-25-000094","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.","GAAP net loss $(5.4)M ($(0.07)/diluted share); adjusted EPS $0.54 vs $0.41 YoY.","Codman Specialty Surgical revenues $292.6M (+8.1% reported); Tissue Technologies $109.5M (-0.5% reported).","Full-year 2025 revenue guidance cut to $1.620B-$1.640B (organic growth -1.6% to -0.4%); adj EPS $2.19-$2.24.","Relaunched PriMatrix and Durepair ahead of schedule; Braintree facility on track for production in June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":1200320000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148927,"accession_number":"0000917520-25-000069","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.","GAAP net loss $484.1M includes $511M goodwill impairment; adjusted EBITDA $71.2M (17.1% margin) vs $83.8M (20.0%) prior year.","Full-year 2025 revenue guidance narrowed to $1.655B–$1.680B; adj EPS reaffirmed at $2.19–$2.29.","Net debt $1.59B; total leverage ratio 4.5x; liquidity ~$1.14B including $254M cash and short-term investments.","Completed all manufacturing site baseline assessments under Compliance Master Plan; no new shipping holds in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":798258000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167848,"accession_number":"0000917520-25-000060","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.","Ratio steps down to 4.75:1 (Sep 2026), 4.50:1 (Dec 2026), and 4.00:1 (Mar 2027 onward).","No increase in total indebtedness; temporary restrictions on investments, liens, and restricted payments during Covenant Relief Period.","Amendment effective June 6, 2025, to Seventh Amended and Restated Credit Agreement dated March 24, 2023.","Company temporarily prohibited from using leverage 'step-up' for permitted acquisitions during Covenant Relief Period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167847,"accession_number":"0000917520-25-000052","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Integra LifeSciences shareholders approve 2.2M share increase in equity plan; chairman transitions to non-executive role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved Amendment No. 2 to increase shares under equity plan by 2.2M, to 20.7M total.","All nine director nominees elected at May 9 annual meeting; PwC ratified as auditor; say-on-pay approved.","Board approved transition of Dr. Essig from Executive Chairman to non-executive Chairman effective July 1, 2025; no disagreement.","Plan amendment eliminates provision allowing shares withheld for taxes to be returned to the plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167846,"accession_number":"0000917520-25-000038","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).","Adjusted EPS $0.41 vs $0.55 prior year; adjusted gross margin 62.2% vs 64.4%.","Codman Specialty Surgical organic revenue -1.1%; Tissue Technologies organic -9.1%.","Full-year 2025 revenue reaffirmed $1.65B-$1.715B; adj EPS guidance reduced to $2.19-$2.29 (incl $(0.22) tariff impact).","Q2 2025 guidance: revenue $390M-$400M, adj EPS $0.40-$0.45; operating cash flow negative $(11.3)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":382653000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185095,"accession_number":"0000917520-25-000014","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q4 adj EPS $0.97 (+9% YoY); FY24 GAAP EPS ($0.09); 2025 adj EPS guidance $2.41-$2.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.","FY2024: rev $1,610.5M (+4.5% rep, -1.3% org); GAAP EPS ($0.09) vs $0.84; adj EPS $2.56 vs $3.10.","FY2025 guidance: rev $1,650M-$1,715M (+2.4-6.5% rep, +1.0-5.0% org); adj EPS $2.41-$2.51 (below 2024 adj EPS $2.56).","Q1 2025 guidance: rev $375M-$385M (+1.6-4.4% rep); org rev -6.2% to -3.5% due to ship holds & Integra Skin delays.","Net debt $1.5B; leverage ratio 4.0x; FY2024 cash from ops $129.4M, capex $104.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1610527000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185094,"accession_number":"0000917520-25-000004","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Integra LifeSciences receives FDA warning letter for quality system violations at three facilities","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter dated Dec 19, 2024, for quality system issues at Mansfield, MA; Plainsboro, NJ; Princeton, NJ facilities.","Products cited: cranial perforators, cottonoid patties, strips, collagen-based products; shipping holds and voluntary recall of patties/strips previously initiated.","Warning letter does not restrict manufacturing/shipment or require recall; premarket approval for related Class III devices blocked until violations resolved.","Company reaffirms Q4 revenue guidance of $441M-$451M; expects no material impact from warning letter.","Company is executing a compliance master plan and preparing a written response to the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201708,"accession_number":"0000917520-24-000121","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Integra LifeSciences adopts Change in Control Severance Program effective Jan 1, 2025, renewing expiring program","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Program covers named executives including CFO Lea Knight, with severance multiple of 2x (1.5x for others) base salary plus target bonus.","Qualifying termination (without cause or for good reason) within 2 years after a change in control triggers lump-sum severance, prorated bonus, COBRA for 18 months, and outplacement.","Program term runs through Dec 31, 2025, with automatic extension upon a change in control until 2-year anniversary.","Benefits subject to general release of claims and potential 'best pay cap' reduction for excise tax under Section 4999."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201707,"accession_number":"0000917520-24-000106","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.","Neurosurgery organic sales -16% on shipping holds; Instruments +8.7%; Tissue Tech -3.7% organic, ex-Boston -9.4%.","FY2024 revenue guidance lowered to $1.609-1.619B (organic -1.7% to -1.0%); adjusted EPS guided $2.41-$2.49.","Mojdeh Poul named next president and CEO, effective Jan 6, 2025, succeeding retiring Jan De Witte.","Shipping holds releasing in line with expectations; Integra Skin production on pace for Q4 historical run rates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":1167881000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201706,"accession_number":"0000917520-24-000105","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Integra LifeSciences names Mojdeh Poul as President & CEO effective Jan 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mojdeh Poul appointed President & CEO, effective January 6, 2025, succeeding Jan De Witte.","Poul previously EVP & Group President of 3M's $8.5B global healthcare business.","Poul to receive base salary of $1.05M, target bonus 125%, and initial equity awards totaling $6.75M.","Jan De Witte's resignation is part of a previously announced succession plan; no disagreement.","Stuart Essig to remain Executive Chairman temporarily before returning to non-executive role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217689,"accession_number":"0000917520-24-000092","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.","Revenue $418.2M, up 9.7% reported, 2.3% organic; organic ex-Boston +0.3%. Adjusted gross margin 65.2% (down from 67.6%).","Codman Specialty Surgical rev $301.8M (+11.3% reported, +0.9% organic). Tissue Technologies $116.4M (+5.6% reported, +5.7% organic; -1% ex-Boston).","FY2024 guidance cut: revenue $1.609-1.629B, adjusted EPS $2.41-2.57. Cites temporary shipping holds and investments in quality/GMP compliance.","Received PMA approvable for SurgiMend pending GMP certification; Braintree facility operational readiness expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":787047000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237591,"accession_number":"0000917520-24-000074","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Integra LifeSciences enters $50M accelerated share repurchase with Morgan Stanley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed ASR agreement on May 16, 2024 with Morgan Stanley & Co. LLC.","Repurchase covers $50M of common stock (par value $0.01).","Transaction expected to be completed in the third quarter of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237590,"accession_number":"0000917520-24-000066","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Integra LifeSciences plans $50M share repurchase; stockholders approve equity plan amendment adding 1.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorizes $50M share repurchase program; repurchases expected to begin Q2 2024 subject to market conditions.","Stockholders approved Plan Amendment: share reserve increased by 1.9M shares; tax withholding share recycling eliminated.","All eight director nominees elected with strong support (>93% of votes cast); PricewaterhouseCoopers ratified as auditor for FY2024.","Stockholders approved charter amendment to limit liability of certain officers as permitted by Delaware law (62.6M for, 9.3M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237589,"accession_number":"0000917520-24-000059","cik":917520,"company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.","Adjusted EPS $0.55 vs $0.74 prior year; adjusted EBITDA $71.8M (19.5% rev) vs $92.3M (24.2%).","Acclarent acquisition closed April 1; FY2024 revenue guidance raised to $1.672-1.687B, adj. EPS guidance $3.01-3.11.","Tissue Technologies revenue fell 15.3% driven by Boston recall; removing SurgiMend/PriMatrix relaunch from guidance due to audit findings.","Codman Specialty Surgical grew 3.3% reported (4.4% organic); Neurosurgery up 6.3% organically, Instruments down 2.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":368872000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181734962.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}